Profound Medical Corp. (PROF) 追踪市盈率为负值 -4.3, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 58.4 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -23.14%, 前瞻盈利收益率 1.71%. PEG 0.29 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 81/100 其中 5/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -4.5 | 0.11 | 4.91 | 0.00 | - |
| 2017 | -5.0 | 0.30 | 6.67 | 19.23 | - |
| 2018 | -8.7 | 0.23 | 6.80 | 69.63 | - |
| 2019 | -10.4 | 1.21 | 10.95 | 37.77 | - |
| 2020 | -16.4 | 1.63 | 3.65 | 48.68 | - |
| 2021 | -7.5 | -0.37 | 2.85 | 33.44 | - |
| 2022 | -7.9 | 0.99 | 4.36 | 33.95 | - |
| 2023 | -6.3 | 2.90 | 5.76 | 24.98 | - |
| 2024 | -7.0 | 0.34 | 3.08 | 18.29 | - |
| 2025 | 5.6 | -0.02 | 2.61 | 14.53 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-2.93 | $0.00 | $-12.15M | - |
| 2017 | $-2.44 | $3.9M | $-14.97M | -383.8% |
| 2018 | $-1.52 | $1.91M | $-15.24M | -797.9% |
| 2019 | $-1.39 | $4.23M | $-15.46M | -365.3% |
| 2020 | $-1.25 | $7.3M | $-21.62M | -296% |
| 2021 | $-1.50 | $6.87M | $-30.7M | -446.7% |
| 2022 | $-1.38 | $6.68M | $-28.67M | -429.1% |
| 2023 | $-1.35 | $7.2M | $-28.57M | -396.8% |
| 2024 | $-1.12 | $10.68M | $-26.48M | -247.9% |
| 2025 | $1.41 | $16.38M | $42.32M | 258.4% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-0.94 | $-1.20 – $-0.77 | $30.54M | $29.29M – $31.47M | 4 |
| 2027 | $-0.78 | $-1.56 – $-0.26 | $48.83M | $47.09M – $52.12M | 4 |
| 2028 | $0.11 | $0.10 – $0.12 | $76.05M | $73.39M – $79.45M | 3 |
| 2029 | $0.56 | $0.53 – $0.59 | $106.34M | $102.62M – $111.1M | 2 |
| 2030 | $1.00 | $0.95 – $1.06 | $150.21M | $144.95M – $156.93M | 2 |
